DETECT V/CHEVENDO - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

被引：2
|
作者：
Krause, S.
Friedl, T.
Fehm, T.
Romashova, T.
Fasching, P. A.
Schneeweiss, A.
Mueller, V.
Taran, F-A
Polasik, A.
Tzschaschel, M.
De Gregorio, A.
Meier-Stiegen, F.
Janni, W.
Huober, J.
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Heinrich Heine Univ Dusseldorf, Dusseldorf, Germany
[3] Univ Hosp Erlangen, Erlangen, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[7] Univ Hosp Tubingen, Tubingen, Germany
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy
    Brufsky, Adam
    Zulfiqar, Malik
    Peguero, Julio
    Lathrop, Kate
    Bhat, Gajanan
    Lebel, Francois
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [43] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [44] Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
    Cheng, Li-Jen
    Loke, Lydia
    Lim, Elaine Hsuen
    Pearce, Fiona
    Aziz, Mohamed Ismail Abdul
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) : 449 - 456
  • [45] Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis
    DeBusk, Kendra
    Abeysinghe, Shaun
    Vickers, Adrian
    Nangia, Anubhav
    Bell, Judith
    Ike, Chiemeka
    Forero-Torres, Andres
    Blahna, Matthew T.
    FUTURE ONCOLOGY, 2021, 17 (33) : 4635 - 4647
  • [46] Differential gene expression analysis and correlation with outcome in HER2-positive metastatic breast cancer treated with HER2-targeted therapy
    Badve, S. S.
    Li, L.
    Thorat, M. A.
    Gagnon, R. C.
    Ellis, C. E.
    O'Shaughnessy, J.
    Blackwell, K. L.
    Baselga, J.
    Sledge, G. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Dual-targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab
    Shu, Mengjun
    Gao, Feng
    Yu, Chulang
    Zeng, Min
    He, Guili
    Wu, Yan
    Su, Yanjie
    Hu, Nantao
    Zhou, Zhihua
    Yang, Zhi
    Xu, Lin
    NANOTECHNOLOGY, 2020, 31 (33)
  • [48] First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy
    Rier, Hanah N.
    Levin, Mark-David
    van Rosmalen, Joost
    Bos, Monique M. E. M.
    Drooger, Jan C.
    de Jong, Paul
    Portielje, Johanneke E. A.
    Elsten, Elisabeth M. P.
    ten Tije, Albert-Jan
    Sleijfer, Stefan
    Jager, Agnes
    ONCOLOGIST, 2017, 22 (08): : 901 - 909
  • [49] Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
    Zhang, Yanqiang
    Xu, Xiaoqing
    Hu, Can
    Du, Yian
    Ding, Guangyu
    Chen, Jiahui
    Zhu, Xiu
    Xu, Zhiyuan
    Wei, Qing
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (07) : 2145 - 2156
  • [50] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
12345